OpenADMET have just announced the ExpansionRx-OpenADMET blind challenge in partnership with Expansion Therapeutics.
Expansion Therapeutics have decided to make all the ADMET publicly available.
“We have decided to release all of our ADME datasets from our programs to the public, and we’re asking the scientific community to put them to work. We do this because we believe open science is the fastest and most reliable path to new and better computational tools that will help patients. To translate this principle into progress, we are collaborating with OpenADMET to launch a blind challenge
The Challenge
Starting October 27th, participants will be tasked with solving real-world ADMET prediction problems ExpansionRx faced during lead optimization. Specifically, you will be asked to predict the ADMET properties of late-stage molecules based on earlier-stage data from the same campaigns. There will be a total of ten (10) endpoints that participants will be asked to predict.
More information about this challenge and the ADMET dataset will be coming soon.
